成骨不全
医学
双膦酸盐
养生
骨骼疾病
康复
结缔组织
生物信息学
物理疗法
骨质疏松症
内科学
病理
生物
作者
Frank Rauch,Francis H. Glorieux
出处
期刊:The Lancet
[Elsevier BV]
日期:2004-04-01
卷期号:363 (9418): 1377-1385
被引量:980
标识
DOI:10.1016/s0140-6736(04)16051-0
摘要
Osteogenesis imperfecta is a genetic disorder of increased bone fragility, low bone mass, and other connective-tissue manifestations. The most frequently used classification outlines four clinical types, which we have expanded to seven distinct types. In most patients the disorder is caused by mutations in one of the two genes encoding collagen type 1, but in some individuals no such mutations are detectable. The most important therapeutic advance is the introduction of bisphosphonate treatment for moderate to severe forms of osteogenesis imperfecta. However, at present, the best treatment regimen and the long-term outcomes of bisphosphonate therapy are unknown. Although this treatment does not constitute a cure, it is an adjunct to physiotherapy, rehabilitation, and orthopaedic care. Gene-based therapy presently remains in the early stages of preclinical research.
科研通智能强力驱动
Strongly Powered by AbleSci AI